Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05644808 · ClinicalTrials.gov registry record
MYLUNG Consortium Study Protocol 2
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by US Oncology Research.
- Active
- Registry status
- 1,002
- Enrollment target
- 18
- Study locations
NCT05644808: Active study of Carcinoma, Non-Small Cell Lung, sponsored by US Oncology Research.
NCT05644808 is a study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by US Oncology Research. The registered enrollment target is 1,002 participants, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (217% higher). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05644808, a study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by US Oncology Research.
- ACTIVE NOT RECRUITING
- Registry status
- 1,002 participants
- Enrollment target
- 18
- Study locations
Study Summary
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Primary Outcome
i. Comprehensive testing is defined as both PD-L1 testing to guide use of immunotherapies \& testing for all genomic alterations for which we have FDA-approved therapies incl EGFR, ALK, ROS1, BRAF, NTRK, RET, KRAS \& MET ii. Document whether patient receives single gene testing for actionable mutations compared to those who receive comprehensive testing. For patients who start systemic therapy prior to or without biomarker results, we will catalog reasons for not conducting testing incl: 1. Cli
Conditions Studied
Study Locations (18)
Texas
- Texas Oncology - West Texas - Abilene
- Texas Oncology- DFWW - Arlington
- Texas Oncology-Dallas Presbyterian Hospital - Dallas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
- Texas Oncology - Fort Worth Cancer Center - Fort Worth
- Texas Oncology-McAllen - McAllen
- Texas Oncology- Northeast Texas - Tyler
Virginia
- Virginia Cancer Specialists, PC - Fairfax
- Virginia Oncology Associates - Newport News
Alabama
- Southern Cancer Center, PC - Daphne
Colorado
- Rocky Mountain Cancer Center - Denver
Florida
- Woodlands Medical Specialists, PA - Pensacola
Illinois
- Illinois Cancer Specialists - Niles
Maryland
- Maryland Oncology Hematology, P.A. - Silver Spring
Minnesota
- Minnesota Oncology Hematology, P.A. - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2027-12 |
What the registry record for NCT05644808 still lists
NCT05644808 is an observational study that tracks outcomes without assigning an intervention. Its 1,002 participants enrollment target places it among the larger protocols in the corpus, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (217% higher).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.
NCT05644808 lists 18 locations in 11 states (Texas, Virginia, Alabama).
Frequently Asked Questions
What is clinical trial NCT05644808 about?
NCT05644808 is a clinical study titled "MYLUNG Consortium Study Protocol 2". This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-...
What is the current status of trial NCT05644808?
This trial is currently active not recruiting. The enrollment target is 1,002 participants. The study started on 2020-12-29. Estimated completion is 2027-12.
What conditions does trial NCT05644808 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
Who is sponsoring clinical trial NCT05644808?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05644808 being conducted?
This trial has 18 study locations across Alabama, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05644808's enrollment target sits among peer trials
1,002 7th of 130 higher than 124 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI